Sorry, you need to enable JavaScript to visit this website.

dbh

Department of Behavioral Health
 

DC Agency Top Menu

Office of Opioid Abatement

The District of Columbia continues to advance its opioid abatement strategy through landmark multi‑settlement agreements that hold pharmaceutical manufacturers and distributors accountable for their role in the opioid crisis. Through these agreements, the District will receive more than $80 million over 18 years to mitigate opioid‑related harm and strengthen community prevention, treatment, recovery, and harm‑reduction services. 

The Office of Opioid Abatement (OOA), established under the Opioid Litigation Proceeds Act of 2021, oversees the distribution, monitoring, and compliance of funds allocated through the Opioid Abatement Fund. The Office is fully staffed with a Director, Grants Management Specialist, Program Analysis Specialist, and Staff Administrator, ensuring strong operational capacity to manage grantmaking, stakeholder engagement, fiscal tracking, and performance oversight.

Since implementation began, OOA has awarded approximately $28 million to support evidence‑based and community‑driven approaches including youth prevention programming, treatment expansion, transitional housing, harm‑reduction services, peer workforce development, targeted outreach, and data surveillance. These investments align with OOA’s mission to ensure all settlement dollars meaningfully reduce opioid harm and strengthen systems of care across the District.

Opioid Abatement Fund Deposits

The Office of Opioid Abatement maintains transparency in reporting expenditures from the Opioid Abatement Fund. As outlined in the Spending Report, the District has received more than $28.5 million in settlement deposits, with $14.4 million already expended across FY24 and FY25. FY24 expenditures totaled $1,140,114.31, while FY25 spending reached $13,295,449.08 across prevention, harm reduction, youth programming, data infrastructure, treatment, and community outreach initiatives.

FY26 expenditures demonstrate continued growth across peer workforce development, youth services, transitional housing, physician training programs, harm reduction expansion, and targeted outreach. 

Remitter Name

Payment Date

Amount Received
McKinsey

4/1/2021

$897,620.83 

McKinsey

4/1/2022

$46,334.23 

McKesson

5/31/2022

$1,838,652.11 

McKesson

9/15/2022

$2,082,409.82 

Johnson & Johnson 

10/18/2022

$6,638,061.12 

McKinsey  

4/3/2023

$46,334.23 

Mallinckrodt

5/24/2023

$275,365.55 

Johnson & Johnson 

6/16/2023

$75,705.79 

McKesson

8/2/2023

$2,055,574.13 

Mallinckrodt

11/9/2023

$323,959.47 

Allergan Payment 1

1/31/2024

$555,142.32 

CVS Payment 1

1/31/2024

$618,190.36 

Teva Payment 1

1/31/2024

$500,960.07 

Walgreens Payment 1

1/31/2024

$715,166.18 

Walgreens Payment 2

1/31/2024

$481,099.72 

Walmart Payment 1

1/31/2024

$1,871,257.28 

Walmart  

2/29/2024

$2,992,707.92 

Manufacturers & Trust 

3/15/2024

$940,237.95 

Publics Health LLC

3/27/2024

$617,322.76 

Publics Health LLC

4/1/2024

$5,000.00 

McKinsey

4/3/2024

$46,334.23 

Manufacturers & Trust-Janssen

6/17/2024

$70,298.23 

CVS Payment  2

7/31/2024

$494,600.34 

Manufacturers & Trust 

7/31/2024

$2,136,187.97 

Allergan Payment 2

7/31/2024

$560,217.20 

Teva Payment 2

8/2/2024

$553,542.44 

Endo Public Opioid Trust

10/10/2024

$566,957.24 

Endo Public Opioid Trust

10/10/2024

$24,792.10 

National Opioids Trust Walgreens

1/15/2025

$9,042.27 

Kroger Section IV.C ( ref 2504301302577)

3/31/2025

$201,578.86 

Kroger Section IV.C ( ref 2504301302578)

3/31/2025

$201,578.86 

Walgreens #3

3/31/2025

$472,057.46 

McKinsey

4/3/2025

$46,334.23 

Mallinckrodt  

4/30/2025

$83,349.57 

Manufacturers & Trust

8/8/2025

$1,922,569.17 

National Opioid Trust CVS

8/8/2025

$935,719.36 

National Opioid Trust Allergan

8/8/2025

$504,195.48 

National Opioid Trust Teva

8/8/2025

$498,188.20 

National Opioids Trust Walgreens

9/15/2025

$68,908.97 

Total 

$32,973,554.02

Download the complete expenditure dataset. 

Grantee Contacts & Community Resources

The Office of Opioid Abatement maintains a public directory of grantee contact information so District residents and community partners can directly access organizations providing opioid prevention, harm reduction, treatment, youth programming, housing stabilization, peer support, and outreach services. These grantee organizations serve as important community resources as the District continues to expand its opioid abatement response. The Anacostia Coordinating Council (ACC) manages the CareLink program and the CareLink Resource Guide, which provides general listings of community services available across Wards 7 and 8. Access the CareLink Resource Guide here: DC CareLink Resource Guide


Download the full Grantee Contact Table.


Organizations seeking future funding may visit the DC Department of Behavioral Health’s Request for Applications page.

Annual Reports

FY 24 Office of Opioid Abatement Annual Report. 

Collaborative Partners

The OOA works in collaboration with the Opioid Abatement Advisory Commission (OAAC). Additional information regarding the OAAC including past and upcoming meetings please visit the OAAC website Opioid Abatement Advisory Commission | dbh.

DC Opioid Overdose Dashboard This dashboard provides in-depth analysis surrounding events and characteristics of individuals who experienced non-fatal and/or fatal opioid overdoses in the District of Columbia.

 For more information concerning the District’s overall approach to saving lives from the opioid epidemic, please visit the LIVE. LONG. DC. (LLDC) website.